ZYTHERA

ZYTHERA is at the forefront of developing groundbreaking treatments for lysosomal storage diseases (LSDs), a diverse group rare metabolic disorders caused by enzyme deficiencies that lead to the accumulation of harmful substances in cells. Our mission is to transform the lives of patients by delivering highly effective and innovative enzyme replacement therapies (ERT). We are committed to researching, developing, and commercializing state-of-the-art enzyme replacement therapies that address the unmet medical needs of those suffering from lysosomal storage diseases. Our focus is on delivering therapies that are not only safe and effective but also accessible to patients worldwide. We utilize state-of-the-art artificial intelligence and engineering biology technologies to accelerate the discovery and development of novel ERTs. Our robust development pipeline includes multiple ERT candidates at various stages of development, focusing on both well-established and ultra-rare lysosomal storage disorders. Patient-centricity is at the core of everything we do. We work closely with patient advocacy groups and healthcare providers to ensure our therapies address the real-world needs of patients and their families. Our ultimate goal is to continually innovate and provide new hope and treatment options for patients worldwide.